UCLA IRB # 06-04-016 "PHASE II TRIAL OF BEVACIZUMAB IN COMBINATION WITH TEMOZ

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，但不一定是研究者所在的机构。 具体目标： 主要目的 研究贝伐珠单抗联合替莫唑胺/放疗在新诊断胶质母细胞瘤患者中的安全性和耐受性 估计接受贝伐珠单抗/替莫唑胺/放疗后接受贝伐珠单抗/替莫唑胺治疗2年或直至检测到进展的新诊断胶质母细胞瘤受试者的总生存期。 次要目的 进一步研究贝伐珠单抗/替莫唑胺/放疗后贝伐珠单抗/替莫唑胺的安全性和耐受性。 从冷冻和石蜡化存档肿瘤样本中分离DNA、RNA和蛋白质，以进行评价。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary Aim To investigate the safety and tolerability in newly-diagnosed patients with glioblastoma of the combination of bevacizumab with temozolomide/radiation To estimate the overall survival in subjects with newly-diagnosed glioblastoma treated with bevacizumab/temozolomide/radiation followed by bevacizumab/temozolomide for 2 years or until progression is detected. Secondary Aims To investigate further the safety and tolerability of bevacizumab/temozolomide/radiation followed by bevacizumab/temozolomide. To isolate DNA, RNA, and protein isolated from frozen and paraffinized archival tumor samples for evaluations.